BeOne Medicines (BEIGF) Total Debt (2015 - 2026)

BeOne Medicines (BEIGF) has 12 years of Total Debt data on file, last reported at $1.1 billion in Q1 2026.

• Total Debt for Q1 2026 came in at $1.1 billion, up 16.78% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.1 billion (up 16.78% YoY), and the FY2025 annual result was $1.0 billion, changed 0.12% from the prior year.
• Total Debt climbed to $1.1 billion in Q1 2026 per BEIGF's latest filing, from $1.0 billion in the prior quarter.
• Over five years, Total Debt peaked at $1.6 billion in Q3 2025 and troughed at $209.1 million in Q4 2022.
• A 5-year average of $842.4 million and a median of $923.6 million in 2025 frame the typical range for Total Debt.
• The sharpest annual moves came in 2022 and 2023: Total Debt slumped 66.78% in 2022, then jumped 323.62% in 2023.
• A 5-year view of Total Debt shows it stood at $209.1 million in 2022, then soared by 323.62% to $886.0 million in 2023, then gained by 14.9% to $1.0 billion in 2024, then advanced by 0.12% to $1.0 billion in 2025, then advanced by 5.83% to $1.1 billion in 2026.
• Business Quant data shows BEIGF's Total Debt at $1.1 billion in Q1 2026, $1.0 billion in Q4 2025, and $1.6 billion in Q3 2025.